Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jennifer Ruth Brown, Ph.D., M.D.

Title
Institution
Department
Address
Fax

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA258924 (BROWN, JENNIFER R) Apr 1, 2021 - Mar 31, 2026
    NIH
    Genetic Predisposition to Chronic Lymphocytic Leukemia (CLL)
    Role: Principal Investigator
  2. R01CA213442 (BROWN, JENNIFER R) Mar 1, 2017 - Feb 28, 2022
    NIH
    Unlocking the Potential of PI3K Inhibition in CLL
    Role: Principal Investigator
  3. P01CA206978 (WU, CATHERINE JU-YING) Sep 1, 2016 - Aug 31, 2026
    NIH
    Comprehensive dissection of the CLL genome & phenome to improve patient outcomes
    Role: Co-Principal Investigator
  4. K23CA115682 (BROWN, JENNIFER R) Jul 1, 2005 - Jul 31, 2010
    NIH
    Genetic Alterations in Families with Multiple Lymphomas
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Hillmen P, Eichhorst B, Brown JR, Lamanna N, O'Brien SM, Tam CS, Qiu L, Kazmierczak M, Zhou K, Šimkovic M, Mayer J, Gillespie-Twardy A, Shadman M, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Österborg A, Yimer HA, Salmi T, Ji M, Yecies J, Idoine A, Wu K, Huang J, Jurczak W. Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial. J Clin Oncol. 2022 Nov 17; JCO2200510. PMID: 36395435.
    Citations:    Fields:    
  2. Arribas AJ, Napoli S, Cascione L, Sartori G, Barnabei L, Gaudio E, Tarantelli C, Mensah AA, Spriano F, Zucchetto A, Rossi FM, Rinaldi A, Castro de Moura M, Jovic S, Bordone-Pittau R, Di Veroli A, Stathis A, Cruciani G, Stussi G, Gattei V, Brown JR, Esteller M, Zucca E, Rossi D, Bertoni F. Resistance to PI3Kd inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis. Haematologica. 2022 11 01; 107(11):2685-2697. PMID: 35484662; PMCID: PMC9614536.
    Citations:    Fields:    
  3. Lampson BL, Gupta A, Tyekucheva S, Mashima K, Petrácková A, Wang Z, Wojciechowska N, Shaughnessy CJ, Baker PO, Fernandes SM, Shupe S, Machado JH, Fardoun R, Kim AS, Brown JR. Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia. J Clin Oncol. 2022 Oct 31; JCO2200269. PMID: 36315919.
    Citations:    Fields:    
  4. Naeem A, Utro F, Wang Q, Cha J, Vihinen M, Martindale SP, Zhou Y, Ren Y, Tyekucheva S, Kim AS, Fernandes SM, Saksena G, Rhrissorrakrai K, Levovitz C, Danysh BP, Slowik K, Jacobs RA, Davids MS, Lederer JA, Zain R, Smith CIE, Leshchiner I, Parida L, Getz G, Brown JR. Pirtobrutinib Targets BTK C481S in Ibrutinib-Resistant CLL but Second-Site BTK Mutations Lead to Resistance. Blood Adv. 2022 Oct 26. PMID: 36287227.
    Citations:    Fields:    
  5. Yin Y, Athanasiadis P, Karlsen L, Urban A, Xu H, Murali I, Fernandes SM, Arribas AJ, Hilli AK, Taskén K, Bertoni F, Mato AR, Normant E, Brown JR, Tjønnfjord GE, Aittokallio T, Skånland SS. Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2022 Oct 14; 28(20):4444-4455. PMID: 35998013; PMCID: PMC9588626.
    Citations:    Fields:    Translation:HumansCells
  6. Brown JR. EXABS-179-CLL DEBATE: Sequencing Small Molecules Is the Way to Go. Clin Lymphoma Myeloma Leuk. 2022 Oct; 22 Suppl 2:S81-S82. PMID: 36164242.
    Citations:    Fields:    Translation:Humans
  7. Knisbacher BA, Lin Z, Hahn CK, Nadeu F, Duran-Ferrer M, Stevenson KE, Tausch E, Delgado J, Barbera-Mourelle A, Taylor-Weiner A, Bousquets-Muñoz P, Diaz-Navarro A, Dunford A, Anand S, Kretzmer H, Gutierrez-Abril J, López-Tamargo S, Fernandes SM, Sun C, Sivina M, Rassenti LZ, Schneider C, Li S, Parida L, Meissner A, Aguet F, Burger JA, Wiestner A, Kipps TJ, Brown JR, Hallek M, Stewart C, Neuberg DS, Martín-Subero JI, Puente XS, Stilgenbauer S, Wu CJ, Campo E, Getz G. Molecular map of chronic lymphocytic leukemia and its impact on outcome. Nat Genet. 2022 Nov; 54(11):1664-1674. PMID: 35927489.
    Citations:    Fields:    Translation:HumansCells
  8. Brown JR, Danilov AV, LaCasce AS, Davids MS. PI3K inhibitors in haematological malignancies. Lancet Oncol. 2022 08; 23(8):e364. PMID: 35901825.
    Citations:    Fields:    
  9. Skanland SS, Brown JR. PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here? Haematologica. 2022 Jul 28. PMID: 35899388.
    Citations:    Fields:    
  10. Kaufman M, Yan XJ, Li W, Ghia EM, Langerak AW, Rassenti LZ, Belessi C, Kay NE, Davi F, Byrd JC, Pospisilova S, Brown JR, Catherwood M, Davis Z, Oscier D, Montillo M, Trentin L, Rosenquist R, Ghia P, Barrientos JC, Kolitz JE, Allen SL, Rai KR, Stamatopoulos K, Kipps TJ, Neuberg D, Chiorazzi N. Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia. Front Oncol. 2022; 12:897280. PMID: 35903706; PMCID: PMC9315922.
    Citations:    
  11. Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, Šimkovic M, Shadman M, Österborg A, Laurenti L, Walker P, Opat S, Chan H, Ciepluch H, Greil R, Tani M, Trnený M, Brander DM, Flinn IW, Grosicki S, Verner E, Tedeschi A, Li J, Tian T, Zhou L, Marimpietri C, Paik JC, Cohen A, Huang J, Robak T, Hillmen P. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022 08; 23(8):1031-1043. PMID: 35810754.
    Citations:    Fields:    
  12. Brown JR. Response to Comment on: "Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients". Haematologica. 2022 06 01; 107(6):1491-1492. PMID: 34788990; PMCID: PMC9152971.
    Citations:    Fields:    Translation:Humans
  13. Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, Sun C, Jurczak W, Pagel JM, Ferrajoli A, Patel P, Tao L, Kuptsova-Clarkson N, Moslehi J, Furman RR. Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica. 2022 06 01; 107(6):1335-1346. PMID: 34587719; PMCID: PMC9152976.
    Citations: 3     Fields:    Translation:Humans
  14. Mamidi MK, Mahmud H, Maiti GP, Mendez MT, Fernandes SM, Vesely SK, Holter-Chakrabarty J, Brown JR, Ghosh AK. Idelalisib activates AKT via increased recruitment of PI3Kd/PI3Kß to BCR signalosome while reducing PDK1 in post-therapy CLL cells. Leukemia. 2022 07; 36(7):1806-1817. PMID: 35568768.
    Citations:    Fields:    Translation:Humans
  15. Brunner C, Betzler AC, Brown JR, Andreotti AH, Grassilli E. Editorial: Targeting Bruton Tyrosine Kinase. Front Cell Dev Biol. 2022; 10:909655. PMID: 35557950; PMCID: PMC9086161.
    Citations:    
  16. Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, Barnes JA, O'Brien SM, Chávez JC, Duell J, Rosenwald A, Crombie JL, Ufkin M, Li J, Zhu M, Ambati SR, Chaudhry A, Lowy I, Topp MS. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May; 9(5):e327-e339. PMID: 35366963.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  17. Allan JN, Pinilla-Ibarz J, Gladstone DE, Patel K, Sharman JP, Wierda WG, Choi MY, O'Brien SM, Shadman M, Davids MS, Pagel JM, Yimer HA, Ward R, Acton G, Taverna P, Combs DL, Fox JA, Furman RR, Brown JR. Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies. Haematologica. 2022 04 01; 107(4):984-987. PMID: 34937320; PMCID: PMC8968902.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  18. Gadi D, Griffith A, Wang Z, Tyekucheva S, Rai V, Fernandes SM, Machado JH, Munugalavadla V, Lederer J, Brown JR. Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia. Br J Haematol. 2022 04; 197(2):207-211. PMID: 35170759; PMCID: PMC9263710.
    Citations:    Fields:    Translation:HumansCells
  19. Mato AR, Davids MS, Sharman J, Roeker LE, Kay N, Kater AP, Rogers K, Thompson MC, Rhodes J, Goy A, Skarbnik A, Schuster SJ, Tam CS, Eyre TA, O'Brien S, Nabhan C, Lamanna N, Sun C, Shadman M, Pagel JM, Ujjani C, Brander D, Coombs CC, Jain N, Cheah CY, Brown JR, Seymour JF, Woyach JA. Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare). Clin Cancer Res. 2022 02 15; 28(4):603-608. PMID: 34789482; PMCID: PMC9253788.
    Citations: 1     Fields:    Translation:Humans
  20. Davids MS, Rogers KA, Tyekucheva S, Wang Z, Pazienza S, Renner SK, Montegaard J, Ihuoma U, Lehmberg TZ, Parry EM, Wu CJ, Jacobson CA, Fisher DC, Thompson PA, Brown JR. Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Blood. 2022 02 03; 139(5):686-689. PMID: 34788401; PMCID: PMC8814674.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  21. Kim HT, Baker PO, Parry E, Davids M, Alyea EP, Ho VT, Cutler C, Koreth J, Gooptu M, Romee R, Nikiforow S, Antin JH, Ritz J, Soiffer RJ, Wu CJ, Brown JR. Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. Haematologica. 2021 12 01; 106(12):3219-3222. PMID: 34435483; PMCID: PMC8634179.
    Citations: 2     Fields:    Translation:Humans
  22. Penter L, Gohil SH, Lareau C, Ludwig LS, Parry EM, Huang T, Li S, Zhang W, Livitz D, Leshchiner I, Parida L, Getz G, Rassenti LZ, Kipps TJ, Brown JR, Davids MS, Neuberg DS, Livak KJ, Sankaran VG, Wu CJ. Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History. Cancer Discov. 2021 12 01; 11(12):3048-3063. PMID: 34112698; PMCID: PMC8660953.
    Citations: 4     Fields:    Translation:HumansCells
  23. Smith CIE, Brown JR, Zain R. Editorial: New Insights on Bruton's Tyrosine Kinase Inhibitors. Front Immunol. 2021; 12:804735. PMID: 34887877; PMCID: PMC8650313.
    Citations:    Fields:    Translation:HumansAnimals
  24. O'Brien SM, Brown JR, Byrd JC, Furman RR, Ghia P, Sharman JP, Wierda WG. Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice. Front Oncol. 2021; 11:720704. PMID: 34858810.
    Citations: 2     
  25. Gadi D, Griffith A, Tyekucheva S, Wang Z, Rai V, Vartanov A, Thrash E, Fernandes SM, Lehmberg TZ, Lee B, Martindale SP, Machado JH, Odejide O, Armand P, Fisher DC, Arnason J, Davids MS, Lederer JA, Brown JR. A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia. Leukemia. 2022 03; 36(3):723-732. PMID: 34743191; PMCID: PMC8891037.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  26. Eyre TA, Schuh A, Wierda WG, Brown JR, Ghia P, Pagel JM, Furman RR, Cheung J, Hamdy A, Izumi R, Patel P, Wang MH, Xu Y, Byrd JC, Hillmen P. Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study. Lancet Haematol. 2021 Dec; 8(12):e912-e921. PMID: 34735860.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  27. Sandova V, Pavlasova GM, Seda V, Cerna KA, Sharma S, Palusova V, Brychtova Y, Pospisilova S, Fernandes SM, Panovska A, Doubek M, Davids MS, Brown JR, Mayer J, Mraz M. IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kd inhibitor idelalisib. Haematologica. 2021 11 01; 106(11):2995-2999. PMID: 34196167; PMCID: PMC8561290.
    Citations: 2     Fields:    Translation:Humans
  28. Biran A, Yin S, Kretzmer H, Ten Hacken E, Parvin S, Lucas F, Uduman M, Gutierrez C, Dangle N, Billington L, Regis FF, Rassenti LZ, Mohammad A, Hoffmann GB, Stevenson K, Zheng M, Witten E, Fernandes SM, Tausch E, Sun C, Stilgenbauer S, Brown JR, Kipps TJ, Aster JC, Gnirke A, Neuberg DS, Letai A, Wang L, Carrasco RD, Meissner A, Wu CJ. Activation of Notch and Myc Signaling via B-cell-Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia. Cancer Res. 2021 12 15; 81(24):6117-6130. PMID: 34686499; PMCID: PMC8678341.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  29. Merryman RW, Redd R, Jeter E, Wong JL, McHugh K, Reynolds C, Nazzaro M, Varden A, Brown JR, Crombie JL, Davids MS, Fisher DC, Jacobsen E, Jacobson CA, Kim AI, LaCasce AS, Ng SY, Odejide OO, Parry EM, Dahi PB, Nieto Y, Joyce RM, Chen YB, Herrera AF, Armand P, Ritz J. Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. Transplant Cell Ther. 2022 01; 28(1):32.e1-32.e10. PMID: 34670169; PMCID: PMC8792205.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  30. Davids MS, Lampson BL, Tyekucheva S, Wang Z, Lowney JC, Pazienza S, Montegaard J, Patterson V, Weinstock M, Crombie JL, Ng SY, Kim AI, Jacobson CA, LaCasce AS, Armand P, Arnason JE, Fisher DC, Brown JR. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. Lancet Oncol. 2021 10; 22(10):1391-1402. PMID: 34534514.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  31. Crombie JL, Sherman AC, Cheng CA, Ryan CE, Zon R, Desjardins M, Baker P, McDonough M, Izaguirre N, Bausk B, Krauss J, Gilboa T, Senussi Y, Walt DR, Davids MS, Brown JR, Armand P, Baden LR, Issa N. Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies. Blood Adv. 2021 08 24; 5(16):3062-3065. PMID: 34387646; PMCID: PMC8362656.
    Citations: 4     Fields:    Translation:HumansCells
  32. Crombie JL, Brown JR. The future of antibody therapy in chronic lymphocytic leukemia. Expert Opin Emerg Drugs. 2021 09; 26(3):323-336. PMID: 34375544.
    Citations: 1     Fields:    Translation:Humans
  33. Wagner-Johnston ND, Sharman J, Furman RR, Salles G, Brown JR, Robak T, Gu L, Xing G, Chan RJ, Rajakumaraswamy N, Gopal AK. Idelalisib immune-related toxicity is associated with improved treatment response. Leuk Lymphoma. 2021 12; 62(12):2915-2920. PMID: 34319205; PMCID: PMC9247649.
    Citations: 2     Fields:    Translation:Humans
  34. Ruppert AS, Booth AM, Ding W, Bartlett NL, Brander DM, Coutre S, Brown JR, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma CS, Abramson JS, Little RF, Smith SE, Stone RM, Byrd JC, Mandrekar SJ, Woyach JA. Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. Leukemia. 2021 10; 35(10):2854-2861. PMID: 34274940; PMCID: PMC8744070.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  35. Murali I, Kasar S, Naeem A, Tyekucheva S, Khalsa JK, Thrash EM, Itchaki G, Livitz D, Leshchiner I, Dong S, Fernandes SM, Getz G, Johnson A, Brown JR. Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia. Blood. 2021 07 08; 138(1):44-56. PMID: 33684943; PMCID: PMC8493976.
    Citations: 7     Fields:    Translation:HumansCells
  36. Wierda WG, Rawstron A, Cymbalista F, Badoux X, Rossi D, Brown JR, Egle A, Abello V, Cervera Ceballos E, Herishanu Y, Mulligan SP, Niemann CU, Diong CP, Soysal T, Suzuki R, Tran HTT, Wu SJ, Owen C, Stilgenbauer S, Ghia P, Hillmen P. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. Leukemia. 2021 11; 35(11):3059-3072. PMID: 34168283; PMCID: PMC8550962.
    Citations: 3     Fields:    Translation:Humans
  37. Ahn IE, Brown JR. Targeting Bruton's Tyrosine Kinase in CLL. Front Immunol. 2021; 12:687458. PMID: 34248972.
    Citations: 8     Fields: